Triangleyttrium-90 radioembolization (NCT06555133)
yttrium-90 radioembolization trial for Colorectal Carcinoma Metastatic in the Liver (NCT06555133). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable colorectal cancer mainly in the liver, progressing after at least two treatment lines. Known MSI-high, mismatch-repair-deficient, or high-mutational-burden tumors are excluded.
The idea: yttrium-90 radioembolization treats liver tumors, combined with oral capecitabine chemotherapy and atezolizumab, which blocks PD-L1. Capecitabine is taken twice daily for two weeks starting with each radioembolization. Atezolizumab is infused every three weeks for five doses. Researchers measure liver disease control at twelve weeks.
This phase 2 study plans 18 patients. Brown University sponsors the sole recruiting US site in Providence.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.